As known, EGFR mutations, being deemed to be a biological marker of NSCLC in recent decades, account for 10%‐25% of NSCLC.53 As a result of its constitutive activation of EGFR signaling and oncogenic transformation, EGFR was confirmed to be an independent risk factor and served as a crucial role.54 So, it is meaningful to evaluate metastatic characteristics in patients with EGFR mutation during clinical screening and treatment.55 This evidence concerns the gene EGFR and non-small cell lung carcinoma.